menu
    • menu
    [{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Boxcar PMJ","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"KRAS","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Immuneering Corporation","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.02,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Boxcar PMJ","highestDevelopmentStatusID":"1","companyTruncated":"Immuneering Corporation \/ Boxcar PMJ"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM-6-415","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"IMM-1-104","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Jefferies"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IMM-6-415","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"IMM-6-415","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immuneering Corporation \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Immuneering Corporation

    Menu

    Immuneering Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuneering Granted Orphan Drug Status for IMM-1-104 in Pancreatic Cancer

                            Details : IMM-1-104 is an oral, once-daily deep cyclic inhibitor, small molecule drug. It is being evaluated for pancreatic ductal adenocarcinoma with gemcitabine and nab-paclitaxel.

                            Brand Name : IMM-1-104

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 15, 2024

                            Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuneering Reports Ph 2 Data for IMM-1-104 with Chemotherapy in Pancreatic Cancer

                            Details : IMM-1-104 is an oral, once-daily deep cyclic inhibitor, small molecule drug. It is being evaluated for pancreatic ductal adenocarcinoma with gemcitabine and nab-paclitaxel.

                            Brand Name : IMM-1-104

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 12, 2024

                            Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

                            Details : IMM-1-104 is an oral, once-daily deep cyclic inhibitor, small molecule drug. It is being evaluated for the treatment of patients with RAS-mutant pancreatic ductal adenocarcinoma.

                            Brand Name : IMM-1-104

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 31, 2024

                            Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMM-6-415

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Dosed In Phase 1/2a Of IMM-6-415 For Solid Tumors With RAF/RAS Mutations

                            Details : IMM-6-415 is a Deep Cyclic Inhibitor (DCI) of the MAPK pathway designed with unique drug-like properties. It is being evaluated for the treatment of advanced solid tumors with RAF or RAS mutations.

                            Brand Name : IMM-6-415

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 27, 2024

                            Lead Product(s) : IMM-6-415

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuneering Announces Positive Phase 1 Data for IMM-1-104 in Solid Tumors

                            Details : IMM-1-104 aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, through deep cyclic inhibition of MEK of the MAPK pathway.

                            Brand Name : IMM-1-104

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 14, 2024

                            Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuneering Doses First Patient in Phase 2a Trial of IMM-1-104 in RAS-mutant Solid Tumors

                            Details : IMM-1-104 is an oral, once-daily deep cyclic inhibitor, small molecule drug. It is being evaluated for the treatment of patients with RAS-mutant pancreatic ductal adenocarcinoma.

                            Brand Name : IMM-1-104

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 11, 2024

                            Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

                            Details : IMM-1-104 is an oral, once-daily deep cyclic inhibitor, small molecule drug. It is being evaluated for the treatment of patients with pancreatic ductal adenocarcinoma.

                            Brand Name : IMM-1-104

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 20, 2024

                            Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMM-6-415

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Sol...

                            Details : IMM-6-415 is a deep cyclic inhibitor (DCI) of the MAPK pathway designed with unique drug-like properties. It is being evaluated for the treatment of advanced solid tumors with RAF or RAS mutations.

                            Brand Name : IMM-6-415

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 12, 2023

                            Lead Product(s) : IMM-6-415

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMM-1-104

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid T...

                            Details : IMM-1-104 aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, through deep cyclic inhibition of the MAPK pathway with once-daily oral dosing.

                            Brand Name : IMM-1-104

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 05, 2023

                            Lead Product(s) : IMM-1-104

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Immuneering Corporation

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMM-1-104

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Jefferies

                            Deal Size : $30.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Immuneering Announces $30 Million Underwritten Offering

                            Details : Immuneering intends to use the net proceeds to advance the preclinical and clinical development of its product candidates, including IMM-1-104, a novel, allosteric dual-MEK inhibitor designed for better applicability to RAS mutant tumors by preventing ME...

                            Brand Name : IMM-1-104

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 18, 2023

                            Lead Product(s) : IMM-1-104

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Jefferies

                            Deal Size : $30.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth